Accessibility Menu
bioMérieux logo

bioMérieux(OTC) BMXMF

Market Cap$10.23BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2004)+139%
5 Year-28%
1 Year-38%
1 Month+10%
$86.88
-1.05%
-0.92Today
bioMérieux last closing stock price
MetricPriceDate
Last closeUSD 86.882026-09-02
bioMérieux stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-1.82%USD 88.502026-08-25
1 month+9.99%USD 78.992026-07-23
3 month+3.17%USD 84.212026-06-04
Year to date-32.78%USD 129.252025-12-30
1 year-38.05%USD 140.252025-08-29
3 year-15.28%USD 102.552023-08-31
5 year-27.86%USD 120.432021-08-31
Since inception+139.18%USD 36.322004-07-22

bioMérieux Financials at a Glance

Market Cap

$10.23BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€8.11B

Net Income (TTM)

€839.87M

EPS (TTM)

$4.55

P/E Ratio

18.98

Dividend

$1.13

Beta (Volatility)

0.25 (Low)

Price

$86.88

Volume

50

Open

$86.88

Previous Close

$86.88

Daily Range

$86.88 - $86.88

52-Week Range

$77.00 - $140.25

Estimated Earnings Date

Mar 4, 2027

BMXMF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About bioMérieux

bioMérieux S.A. is a global leader in in vitro diagnostic solutions, specializing in the detection of infectious diseases, cardiovascular conditions, and various cancers. Founded in 1963 and headquartered in Marcy l'Etoile, France, the company serves a diverse clientele, including clinical laboratories, medical professionals, and industrial control facilities.

Products and Services
  • In vitro diagnostic systems for infectious diseases and cancers
  • Microbiological testing for food, pharmaceutical, and veterinary industries
  • Comprehensive solutions for clinical and hospital laboratories
Growth Outlook
  • Projected revenue growth driven by increasing demand for diagnostic solutions
  • Expansion into emerging markets enhances global footprint
  • Investment in R&D supports innovation and product development
Financial Highlights
  • Recent quarterly revenue of €1.96 billion, reflecting strong market demand
  • Net income of €225.76 million, showcasing profitability
  • TTM P/E ratio of 19.15 indicates reasonable valuation compared to industry peers
bioMérieux S.A. operates in the healthcare sector, focusing on medical diagnostics and research. The company has demonstrated resilience and growth potential, with a market capitalization of approximately $10.36 billion. The recent quarterly results indicate a robust revenue stream, supported by a solid net income margin of 11.5%. The company's commitment to research and development is evident, with significant investments aimed at enhancing its product offerings. With a stable dividend yield of 1.30%, bioMérieux presents an attractive opportunity for investors interested in the healthcare diagnostics sector. The company's strategic initiatives and strong financial performance position it well for future growth in a rapidly evolving market.
AI Generated • Aug 30, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

15,078

CEO

Pierre Boulud

Website

www.biomerieux.com

Headquarters

Marcy l'Étoile, ARA 69280, FR

BMXMF Financials

Key Financial Metrics (TTM)

Gross Margin

52.04%

Operating Margin

11.99%

Net Income Margin

11.59%

Return on Equity

11.01%

Return on Capital

14.35%

Return on Assets

8.12%

Earnings Yield

5.27%

Dividend Yield

1.30%

Payout Ratio

24.91%

Stock Overview

Market Cap

$10.23BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

117.69M

Volume

50

Avg. Volume

202.859

Financials (TTM)

Gross Profit

€4.39B

Operating Income

€987.49M

EBITDA

€1.89B

Operating Cash Flow

€1.69B

Capital Expenditure

-€670.12M

Free Cash Flow

€1.02B

Cash & ST Invst.

€656.72M

Total Debt

€421.17M

bioMérieux Performance Analysis

bioMérieux annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 3,772,051,920-5.5%
20232023-12-31EUR 3,972,775,5065.3%
20242024-12-31EUR 4,305,021,0418.4%
20252025-12-31EUR 4,593,086,5436.7%
bioMérieux sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-319.3%
Q22025-06-30-1.6%
Q42025-12-31-0.9%
Q22026-06-30-3.1%
bioMérieux annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR 4.01-32.8%
20232023-12-31EUR 3.25-18.9%
20242024-12-31EUR 3.9421.0%
20252025-12-31EUR 3.77-4.1%
bioMérieux sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31N/A
Q22025-06-30-25.8%
Q42025-12-3146.7%
Q22026-06-30-3.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

€1.96B

+3.1%

Gross Profit

€1.08B

+1.8%

Gross Margin

55.18%

N/A

Market Cap

$10.23BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$678.15K

N/A

Employees

15,078

N/A

Net Income

€225.76M

+4.9%

EBITDA

€440.54M

+10.2%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

€656.72M

+141.3%

Total Debt

€421.17M

-24.6%

Accounts Receivable

€960.66M

+38.2%

Inventory

€973.84M

-3.8%

Long Term Debt

€188.32M

-49.6%

Short Term Debt

€233.20M

+26.0%

Return on Assets

8.12%

N/A

Return on Invested Capital

10.48%

N/A

Free Cash Flow

€296.85M

+533.0%

Operating Cash Flow

€436.15M

+121.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TWSTTwist Bioscience Corporation
$128.71-1.75%
ICLRICON Public Limited Company
$163.58+2.34%
CRLCharles River Laboratories International, Inc.
$293.35+0.54%
CDNACareDx, Inc
$49.86+0.52%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$10.38+0.11%
NVDANvidia
$228.45+0.02%
SPCXSpace Exploration Technologies
$149.74+0.06%
BITOProShares Trust - ProShares Bitcoin ETF
$11.01+0.06%

Questions About BMXMF

What is the current price of bioMérieux?

bioMérieux is trading at $86.88 per share.

What is the 52-week range for bioMérieux?

Over the past 52 weeks, bioMérieux has traded between $77.00 and $140.25.

How much debt does bioMérieux have?

As of the most recent reporting period, bioMérieux reported total debt of €541.89M.

How much cash does bioMérieux have on hand?

bioMérieux reported €669.20M in cash and cash equivalents in its most recent financial results.

What is bioMérieux’s dividend yield?

bioMérieux currently has a dividend yield of 1.30%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services